| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Deacetylcefotaxime lactone does not have a defined pharmacological target as an antibiotic. It is a degradation product of cefotaxime and has significantly reduced antibacterial activity compared to the parent compound. The compound may interact with penicillin-binding proteins (PBPs) but with much lower affinity than cefotaxime. Its primary relevance is in pharmaceutical analysis rather than pharmacology.
|
|---|---|
| ln Vitro |
Deacetylcefotaxime lactone has limited antibacterial activity compared to cefotaxime. The deacetylation and lactone formation result in a loss of the β-lactam antibiotic activity. In vitro studies are primarily focused on the analysis of cefotaxime stability and the identification of degradation products rather than on the biological activity of the degradation product itself.
|
| ln Vivo |
Deacetylcefotaxime lactone has no therapeutic activity in vivo. It is a degradation product that may be formed during storage or after administration of cefotaxime. The compound is not administered as a therapeutic agent. Its relevance is in the context of pharmaceutical stability and quality control studies rather than in vivo pharmacology.
|
| Enzyme Assay |
In vitro analytical methods for Deacetylcefotaxime lactone typically involve HPLC (high-performance liquid chromatography) with UV detection. The compound is separated from cefotaxime and other degradation products using reversed-phase chromatography. Identification is confirmed by mass spectrometry or by comparison with reference standards. Stability studies are performed under various conditions (temperature, pH, light) to monitor the formation of degradation products.
|
| Cell Assay |
Deacetylcefotaxime lactone is not used in cell-based assays as it has no significant biological activity. The compound is studied in the context of pharmaceutical analysis rather than cell biology. If cell-based assays were performed, they would likely show minimal antibacterial activity compared to cefotaxime. The compound is primarily relevant to analytical chemistry.
|
| Animal Protocol |
Deacetylcefotaxime lactone is not used in animal studies as it has no therapeutic activity. The compound may be studied in pharmacokinetic studies of cefotaxime to identify metabolites and degradation products. However, as a degradation product with reduced activity, it is not a primary focus of in vivo research. The compound's relevance is in pharmaceutical stability testing.
|
| ADME/Pharmacokinetics |
Deacetylcefotaxime lactone has a molecular weight of approximately 382.41 g/mol and molecular formula C14H14N4O5S2. The compound is a solid and should be stored under standard laboratory conditions for analytical reference standards. It is typically analyzed by HPLC with UV detection. Stability is influenced by temperature, pH, and light exposure.
|
| Toxicity/Toxicokinetics |
Deacetylcefotaxime lactone is a degradation product and not a therapeutic agent. Toxicity data for this compound are limited. As a β-lactam degradation product, it is not expected to have significant toxicity. Standard laboratory safety precautions should be followed when handling the compound. The compound is for analytical research use only.
|
| References | |
| Additional Infomation |
Deacetylcefotaxime lactone is a metabolite and degradation product of the third-generation cephalosporin antibiotic cefotaxime. It is formed by deacetylation of cefotaxime followed by lactone ring formation. The compound is primarily of interest in pharmaceutical analysis for studying the stability of cefotaxime formulations and for identifying degradation products under various storage conditions. Deacetylcefotaxime lactone has significantly reduced antibacterial activity compared to cefotaxime and is not used as a therapeutic agent. It is for research use only as an analytical reference standard.
|
| Molecular Formula |
C14H13N5O5S2
|
|---|---|
| Molecular Weight |
395.408
|
| Exact Mass |
395.035
|
| CAS # |
66340-33-8
|
| PubChem CID |
13080558
|
| Appearance |
White to off-white solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Index of Refraction |
1.904
|
| LogP |
-0.75
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
741
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C4=C(COC4=O)CS3
|
| InChi Key |
MCSWUKXFFGUOQE-GHXIOONMSA-N
|
| InChi Code |
InChI=1S/C14H13N5O5S2/c1-23-18-7(6-4-26-14(15)16-6)10(20)17-8-11(21)19-9-5(2-24-13(9)22)3-25-12(8)19/h4,8,12H,2-3H2,1H3,(H2,15,16)(H,17,20)/b18-7-/t8-,12-/m1/s1
|
| Chemical Name |
(2Z)-2-(2-amino-1,3-thiazol-4-yl)-N-[(4R,5R)-3,11-dioxo-10-oxa-6-thia-2-azatricyclo[6.3.0.02,5]undec-1(8)-en-4-yl]-2-methoxyiminoacetamide
|
| Synonyms |
Ceftriaxone impurity B; 3-Desacetyl Cefotaxime Lactone; Deacetylcefotaxime lactone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~316.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5290 mL | 12.6451 mL | 25.2902 mL | |
| 5 mM | 0.5058 mL | 2.5290 mL | 5.0580 mL | |
| 10 mM | 0.2529 mL | 1.2645 mL | 2.5290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
